MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

166.9B

Vuru Grade

47.84/100

Current Price

$58.54
-0.42 (-0.71%)

Growth Price

$47.52
Overvalued by 18.82%

Stability Price

$23.65
Overvalued by 59.61%

Company Metrics

  • 14.49 P/E
  • 3.98 P/S
  • 3.73 P/B
  • 4.07 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.77 / 3% Dividend
  • 10.82M Avg. Vol.
  • 2.85B Shares
  • 166.9B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Merck & Co., Inc. Gardasil 9 Gets Green Signal From CDC Committee
Bidness ETC - Feb 28, 2015
Pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) announced Thursday that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has included its Gardasil 9 vaccine in the list of recommended ...
Trade of the Day: MRK Stock Fires Off Triple Buy Signals
Investorplace.com - Feb 26, 2015
Merck & Co., Inc. (NYSE:MRK) - This is one of the world's largest drug manufacturers, and recent acquisitions have added to its position in niche markets.
5 Things Merck & Co., Inc.'s Management Wants You to Know
Motley Fool - Feb 7, 2015
Pharmaceutical giant Merck (NYSE: MRK ) offers a number of promising new drug candidates, but unfortunately for investors it delivered another highly forgettable quarter this past week.
Merck & Co., Inc. Collaborates With MPP To Increase Access To Its HIV Drug In ...
Bidness ETC - Feb 25, 2015
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced an agreement with the Medicines Patent Pool (MPP) for its HIV drug, raltegravir, in its efforts to expedite the process of developing low-priced pediatric formulations for ...
New Jersey Drugmaker Grants Free License to HIV Medicine for Children - NBC 10 Philadelphia
One Put, One Call Option To Know About for Merck & Co.
Forbes - Feb 23, 2015
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Merck & Co. Inc. (NYSE:MRK) Partners With MPP to help Developing Countries ...
WallStreet.org - Feb 26, 2015
Merck & Co. Inc. (NYSE:MRK), which is the second biggest drug maker in United States, has announced that it has made an agreement with the MPP (medicine patent pool) for its HIV treatment.
Analyst Rating Update on Merck & Co., Inc.
Stafford Daily - Feb 26, 2015
Merck & Company (NYSE:MRK) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 2 by 12 Wall Street Analysts. 6 analysts have added the counter in their list of strong buys.
Merck & Co. Inc. (NYSE:MRK) Tights Its Shoes To Present New Data of ... - StreetWise Report
What Should You Do With Merck In 2015? (MRK)
Seeking Alpha (registration) - Feb 17, 2015
Merck & Co. (NYSE:MRK) last week announced rather disappointing quarterly and full year 2014 results. The results once again highlighted the loss of revenue due to the patent cliff.
Merck & Co., Inc. Price Target Update - Stafford Daily
Company Watch : Merck & Co. Inc. (NYSE:MRK) - Street Report
Merck & Co., Inc. (MRK) Q4 Earnings Preview: Expect Lower Sales And Earnings
Bidness ETC - Feb 2, 2015
Merck & Co., Inc. (NYSE:MRK) is due to announce its earnings for the fourth quarter of fiscal 2014 (4QFY14) before the market opens February 4. Analysts expect the company to report $10.46 billion in revenue for the quarter, a 7.5% decline from $11.3 ...
Zacks Rating Disclosure on Merck & Co., Inc. - Stafford Daily
Merck & Co., Inc. (MRK) 4Q Results To Reflect Patents Expiry Impact - InvestCorrectly
Merck & Co., Inc. (MRK) No Longer Has Breakthrough Therapy Status For Its ...
Bidness ETC - Feb 4, 2015
Merck & Co., Inc. (NYSE:MRK) announced Wednesday that the US Food and Drug Administration (FDA) has issued a notice detailing plans to rescind its Breakthrough Therapy Designation for the company's hepatitis C treatment drug.
Company Update (NYSE:MRK): Merck says hepatitis C treatment to lose ... - Jutia Group
FDA to Rescind Breakthrough Status for Merck Hepatitis Drug - Bloomberg